Sylvie Froidevaux Selected Research

DOTA- beta- Ala(3)- Nle(4)- Asp(5)- Phe(7)- Lys(10)- (111)indium-alpha-MSH (3-10)

9/2003	Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium.
6/2003	DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions.
12/2002	A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sylvie Froidevaux Research Topics

Disease

11	Neoplasms (Cancer) 01/2010 - 01/2002
8	Melanoma (Melanoma, Malignant) 01/2010 - 02/2002
5	Neoplasm Metastasis (Metastasis) 01/2010 - 06/2003
4	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 05/2011
4	Amelanotic Melanoma (Amelanotic Melanomas) 01/2007 - 12/2002
3	Inflammation (Inflammations) 01/2023 - 05/2011
1	Sialadenitis 11/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020
1	Autoimmune Diseases of the Nervous System 12/2017
1	Multiple Sclerosis 12/2017
1	Hypersensitivity (Allergy) 05/2011
1	Edema (Dropsy) 05/2011
1	Arthritis (Polyarthritis) 05/2011
1	Nervous System Neoplasms (Neoplasms, Nervous System) 04/2002
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 04/2002

Drug/Important Bio-Agent (IBA)

7	alpha-MSHIBA 01/2007 - 02/2002
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2007 - 04/2002
5	Peptides (Polypeptides)IBA 01/2010 - 01/2004
4	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2010 - 01/2002
3	LigandsIBA 01/2023 - 01/2007
3	cenerimodIBA 11/2021 - 12/2017
3	Sphingosine-1-Phosphate ReceptorsIBA 01/2020 - 05/2011
3	RadiopharmaceuticalsIBA 01/2010 - 06/2003
3	Melanocyte-Stimulating Hormones (MSH)IBA 01/2010 - 09/2003
3	acetyl0Nle(4)-Asp(5)-Phe(7)- alpha-MSH (4-11)IBA 01/2007 - 01/2004
3	MelanocortinsIBA 05/2005 - 12/2002
3	DOTA- beta- Ala(3)- Nle(4)- Asp(5)- Phe(7)- Lys(10)- (111)indium-alpha-MSH (3-10)IBA 09/2003 - 12/2002
2	Type 1 Melanocortin ReceptorIBA 01/2007 - 02/2002
2	Lysine (L-Lysine)FDA Link 05/2005 - 01/2004
2	GalliumIBA 01/2004 - 04/2002
2	Radioisotopes (Radionuclides)IBA 09/2003 - 04/2002
1	ChemokinesIBA 01/2023
1	ThiazolesIBA 01/2022
1	seven-transmembrane G-protein-coupled receptorIBA 01/2022
1	Chemokine ReceptorsIBA 01/2022
1	AutoantibodiesIBA 11/2021
1	Fingolimod Hydrochloride (FTY720)FDA Link 12/2017
1	ponesimodIBA 05/2011
1	CytokinesIBA 05/2011
1	AntibodiesIBA 01/2010
1	AmidesIBA 01/2007
1	N-hexanoic-Tyr-Ile-(6) aminohexanoic amideIBA 01/2007
1	glycyllysineIBA 01/2007
1	Chelating AgentsIBA 05/2005
1	AcidsIBA 05/2005
1	MetalsIBA 05/2005
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2004
1	TritiumIBA 09/2003
1	IndiumIBA 09/2003
1	A-factor (Streptomyces)IBA 12/2002
1	4-Nle-7-Phe-alpha- MSHIBA 12/2002
1	IsotopesIBA 04/2002
1	lanreotide (Somatuline)FDA Link 01/2002
1	Hormones (Hormone)IBA 01/2002
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2002
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2002
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2002
1	vapreotideIBA 01/2002

Therapy/Procedure

8	Therapeutics 12/2017 - 01/2002
2	Radiotherapy 04/2002 - 01/2002
1	Oral Administration 12/2017
1	Immunomodulation 05/2011